Ingelheim, Germany (ots/PRNewswire) - - For Non-US Media Only - Boehringer Ingelheim's LUX-Lung Programme Moves Forward With New Studies Revealing the Potential of BIBW 2992 in Personalising Lung Cancer Care - The First Presentation of Data From BIBF 1120 in Ovarian Cancer Boehringer Ingelheim ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. finances/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., May 11, 2009 (euro adhoc) - Key Figures . Revenue: EUR 1.24 million in Q1 2009, up by 36% (Q1 2008: EUR 0.92 million) . EBIT: EUR -2.31 million in Q1 2009, ...
Mumbai (ots/PRNewswire) - - Evaluation Based on Completeness of Vision and Ability to Execute Tata Communications, a leading provider of a new world of communications, today announced it has been positioned by industry analyst firm Gartner, Inc. in the Challengers quadrant of its "Magic Quadrant for ...
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go ...
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media ...
Singapore (ots/PRNewswire) - - Exchanges to be Deployed in India, US and UK Tata Communications, a leading provider of the new world of communications, announced today that it will introduce telepresence exchange services for Cisco TelePresence(TM) (http://www.cisco.com/e n/US/netsol/ns669/networking_solutions_solution_segment_home.html) , a major expansion of its telepresence services. The Global ...
. Total Group revenues up 26.4 percent to EUR 1.53 billion . Profit after tax up 44.5 percent to EUR 107.5 million . Forecast for 2009 confident: total Group revenues of EUR 1.4 billion and profit after tax at 2007 level Corporate news transmitted by euro adhoc. The issuer/originator is ...
Basel, Switzerland (ots/PRNewswire) - New data published today in a major peer-reviewed journal, Annals of Internal Medicine, show that re-treatment with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) provides previously-treated hepatitis C patients a second chance for a cure. The study results ...
Paris (ots/PRNewswire) - Etam's swimsuit collection for Summer 09 is a modern interpretation of the eternal feminine. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/etam/37703/ All of the different silhouettes and necklines are included in this summer's collection: from the modest Italian-style bikini to the draped glamour of the femme fatale. "Jewelled" detailing enhances ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Florence, Italy (ots/PRNewswire) - - Results Presented Today at the Annual Congress of the World Psychiatric Association (WPA) ABILIFY(R) (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I Disorder, who are ...
Bristol-Myers Squibb GmbH & Co. KGaA
London (ots/PRNewswire) - - Between 15 to 38 percent of HIV-infected persons in Europe do not present for screening and treatment until late in infection.(1) Late presentation has been show to result in increased morbidity(1) and decreasing quality of life.(2,3) Almost three decades after the discovery of HIV/AIDS, and despite big medical advances, there ...
Successfully delivering on new partnering deals - PRESEPT clinical trial on track - Product launches expected in 2009 - Financials in line with latest expectations - Two successful financing transactions ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. balance/molecular diagnostics Press Release, ...
Amsterdam (ots/PRNewswire) - - Psoriasis Patients from Around the World Come together to Bare Their Skin and Share Their Stories for New Pan-European Educational Programme AMSTERDAM, March 26 /PRNewswire/ -- Psoriasis: The Naked Truth, a new pan-European educational programme to expose the physical and ...
Sydney (ots/PRNewswire) - Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, that ...
Utrecht, The Netherlands (ots/PRNewswire) - - Industry's Most Powerful and Secure Attended Remote Control and IT Support Offering Helps Channel Partners and IT Professionals Reduce Costs and Improve Customer Service N-able Technologies(R)(http://www.n-able.com/), the global leader in network and systems ...
Indianapolis, U.s.a. and Ingelheim, Germany (ots/PRNewswire) -- - Patients on Treatment Also Experienced Improved Physical Functioning In a new study, duloxetine hydrochloride (Cymbalta(R)), administered at 60 mg to 120 mg taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from ...
Ingelheim, Germany (ots/PRNewswire) - - ESO Recommends Extended Time Window for Actilyse(R) INGELHEIM, Germany, January 30 /PRNewswire/ -- - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R) ...
Maidenhead, England (ots/PRNewswire) - - For the First Time, Children and Adolescents in Europe With Psoriasis are now Able to Benefit From Same Efficacy and Disease Control as Adults The European Commission today granted marketing authorisation of the use of Enbrel(R) (etanercept) as the first biologic ...
Scientific Steering Committee, Machine Preservation Trial
Groningen, The Netherlands (ots/PRNewswire) - Results from a landmark trial published today in the New England Journal of Medicine, show that in transplanted kidneys preserved and transported in a specially designed machine (LifePort Kidney Transporter) the odds for experiencing a delay in recovery of kidney ...
Cork, Ireland (ots/PRNewswire) - - Once-Daily TMC278 is the Third Anti-HIV Compound to be Developed in Tibotec Virology Portfolio Tibotec Pharmaceuticals is currently recruiting HIV-positive, treatment-naïve adults (or those who have never taken antiretroviral medication before) in Europe for two major ...
Beerse, Belgium (ots/PRNewswire) - - Preliminary Phase II Re-treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with ...
Basel (ots/PRNewswire) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment-Experienced Patients Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (0 KD)) plus Copegus(R) (ribavirin) for the ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing ...
Cork, Ireland (ots/PRNewswire) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment-Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA(R) ...
Maidenhead, England, November 21 (ots/PRNewswire) - - Not for UK Journalists The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with ...
Ingelheim, Germany, November 17 (ots/PRNewswire) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II - For non-US Healthcare Media Boehringer Ingelheim has ...
. Total Group revenues up 24.7 percent to EUR 1,112 million . After-tax profit up 74 percent to EUR 67.8 million . Full-year forecast for 2008 reaffirmed ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Schrobenhausen, ...
New Orleans, Louisiana, November 11 (ots/PRNewswire) - - New Post-Hoc Analysis From Athena Study Showed That Multaq(R) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28% in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November 11 /PRNewswire/ ...
Tokyo, November 7 (ots/PRNewswire) - - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their ...
New York (ots/PRNewswire) - - Exclusive Agreement Set to Bring The Beatles Music to Fans for the First Time in Interactive Form Here, There and Everywhere in 2009 The Beatles' extraordinary music and phenomenal legacy is set to rock across the universe in the form of a video game through an exclusive ...